Adell Harriman & Carpenter Inc. Has $1.61 Million Stake in Jazz Pharmaceuticals PLC (JAZZ)

Adell Harriman & Carpenter Inc. lifted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 21.9% during the 1st quarter, HoldingsChannel reports. The firm owned 11,255 shares of the specialty pharmaceutical company’s stock after buying an additional 2,020 shares during the period. Adell Harriman & Carpenter Inc.’s holdings in Jazz Pharmaceuticals were worth $1,609,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at about $25,000. Prime Capital Investment Advisors LLC acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at about $27,000. Carroll Financial Associates Inc. boosted its stake in Jazz Pharmaceuticals by 166.7% in the first quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 125 shares in the last quarter. Osborn Williams & Donohoe LLC acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at about $33,000. Finally, Enlightenment Research LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at about $37,000. 95.33% of the stock is currently owned by institutional investors.

In other news, CFO Matthew P. Young sold 1,916 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $131.46, for a total transaction of $251,877.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Suzanne Sawochka Hooper sold 6,666 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $140.00, for a total value of $933,240.00. Following the transaction, the executive vice president now owns 40,401 shares of the company’s stock, valued at $5,656,140. The disclosure for this sale can be found here. Insiders have sold 11,668 shares of company stock valued at $1,606,567 over the last 90 days. 3.90% of the stock is owned by corporate insiders.



Shares of JAZZ opened at $138.31 on Thursday. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $184.00. The company has a quick ratio of 3.01, a current ratio of 3.15 and a debt-to-equity ratio of 0.63. The stock has a market cap of $7.69 billion, a PE ratio of 11.30, a P/E/G ratio of 1.00 and a beta of 1.16.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a return on equity of 27.35% and a net margin of 24.88%. The company had revenue of $508.19 million during the quarter, compared to the consensus estimate of $466.55 million. During the same period last year, the company earned $2.98 earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 13.2 EPS for the current fiscal year.

Several analysts recently weighed in on the company. ValuEngine raised Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 8th. HC Wainwright reissued a “hold” rating and set a $153.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, May 10th. Zacks Investment Research raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target on the stock in a research note on Tuesday, April 16th. Mizuho lifted their price target on Jazz Pharmaceuticals from $146.00 to $148.00 and gave the company a “neutral” rating in a research note on Wednesday, May 8th. Finally, BMO Capital Markets lifted their price target on Jazz Pharmaceuticals from $206.00 to $208.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $182.41.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://dakotafinancialnews.com/2019/05/16/adell-harriman-carpenter-inc-has-1-61-million-stake-in-jazz-pharmaceuticals-plc-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Different Options Trading Strategies

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.